Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone650-641-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$108.47 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable
Intersect ENT (NASDAQ:XENT) Frequently Asked Questions
What is Intersect ENT's stock symbol?
Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
How were Intersect ENT's earnings last quarter?
Intersect ENT Inc (NASDAQ:XENT) released its quarterly earnings results on Monday, February, 25th. The medical equipment provider reported ($0.16) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.16). The medical equipment provider had revenue of $32.80 million for the quarter, compared to the consensus estimate of $32.68 million. Intersect ENT had a negative net margin of 21.13% and a negative return on equity of 19.04%. Intersect ENT's revenue was up 11.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.11) earnings per share. View Intersect ENT's Earnings History.
When is Intersect ENT's next earnings date?
What guidance has Intersect ENT issued on next quarter's earnings?
Intersect ENT issued an update on its first quarter 2019 earnings guidance on Monday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $26-26.5 million, compared to the consensus revenue estimate of $27.5 million.Intersect ENT also updated its FY 2019 guidance to EPS.
What price target have analysts set for XENT?
6 Wall Street analysts have issued 12-month price objectives for Intersect ENT's shares. Their forecasts range from $28.00 to $48.00. On average, they anticipate Intersect ENT's stock price to reach $39.00 in the next year. This suggests a possible upside of 24.1% from the stock's current price. View Analyst Price Targets for Intersect ENT.
What is the consensus analysts' recommendation for Intersect ENT?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intersect ENT.
What are Wall Street analysts saying about Intersect ENT stock?
Here are some recent quotes from research analysts about Intersect ENT stock:
- 1. BTIG Research analysts commented, "Intersect reported Q4 revenue in line with its preannouncement. Guidance of $123M-$127M (also given previously) remains just below the Street’s $127.2M but not surprising given some conservatism early in the year. The company will no longer guide SINUVA but is aware of Street estimates and will see how sales play out. The big surprise was operating expense guidance of $135-137M which was well above most estimates. We think shares will be pressured Tuesday. While a good portion of this increased spend will be R&D for a new drug-coated balloon, it is also clear that much of XENT’s growth is coming through head count. While Intersect will have significantly more data coming, we continue to remain cautious around reimbursement for SINUVA. We do not know what will happen with the re- proposed J-Code and we are not sure how many insurance companies will decide to pay more than once per year." (2/26/2019)
- 2. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (1/22/2019)
- 3. Northland Securities analysts commented, "We had specifically referenced this drug and these Phase-III studies as risks on the horizon for SINUVA in our note dated 10/03/18. The Phase – III data raise many questions in our mind about SINUVA outlook and the competitive landscape. Caution is warranted vis-a-vis SINUVA. Key Points The f/u for the 2-trials was 24-wks, Dupilumab + mometasone furoate (Nasonex) spray 51% reduction in nasal congestion / obstruction severity vs. 15% for the control arm of mometasone furoate spray in SINUS-24 trial. The numbers stood at 57% and 19% for SINUS-52 trial." (10/17/2018)
- 4. Canaccord Genuity analysts commented, "We remain buyers ahead of trial data coming up in 4Q18 We believe the stock’s pullback presents opportunity ahead of a catalyst-rich period that is coming up in the near to medium-term. Specifically, we await results on long- term safety of rimegepant (acute treatment of migraine) and a Phase 3 trial on the orally-dissolving tablet (ODT) formulation of rimegepant. Given the behavior of the molecule in two Phase 3 trials so far (see here) and a validated mechanism (Allergan also reported positive results for its ubrogepant; see here), we expect these results to support a potential filing of rimegepant in 2019. a more detailed list of BHVN-related catalysts. We also continue to believe that rimegepant could be a meaningful player in the market for the acute treatment of migraine, and we are reiterating our BUY on BHVN." (8/1/2018)
Has Intersect ENT been receiving favorable news coverage?
News stories about XENT stock have been trending somewhat negative this week, InfoTrie reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intersect ENT earned a daily sentiment score of -1.1 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.
Are investors shorting Intersect ENT?
Intersect ENT saw a drop in short interest in February. As of February 15th, there was short interest totalling 1,071,527 shares, a drop of 26.6% from the January 31st total of 1,458,858 shares. Based on an average trading volume of 261,903 shares, the short-interest ratio is presently 4.1 days. Currently, 3.6% of the shares of the stock are short sold. View Intersect ENT's Current Options Chain.
Who are some of Intersect ENT's key competitors?
Some companies that are related to Intersect ENT include Merit Medical Systems (MMSI), Glaukos (GKOS), NuVasive (NUVA), Cantel Medical (CMD), Irhythm Technologies (IRTC), Nevro (NVRO), Atrion (ATRI), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), K2M Group (KTWO), AtriCure (ATRC), Luminex (LMNX), Orthofix Medical (OFIX), Tactile Systems Technology (TCMD) and Cryolife (CRY).
What other stocks do shareholders of Intersect ENT own?
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the folowing people:
- Ms. Lisa D. Earnhardt, CEO, Pres & Director (Age 49)
- Ms. Jeryl L. Hilleman, Chief Financial Officer (Age 61)
- Mr. David A. Lehman, Gen. Counsel & Sec. (Age 58)
- Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 55)
- Ms. Christine R. Kowalski, Chief Operations Officer
Who are Intersect ENT's major shareholders?
Intersect ENT's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.05%), Westfield Capital Management Co. LP (2.24%), Northern Trust Corp (1.32%), Geode Capital Management LLC (1.12%), Geode Capital Management LLC (1.12%) and Broadfin Capital LLC (0.94%). Company insiders that own Intersect ENT stock include Dana G Jr Mead, David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.
Which major investors are selling Intersect ENT stock?
XENT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Citigroup Inc., FMR LLC, Bank of America Corp DE, Barclays PLC, Kopp Investment Advisors LLC, Principal Financial Group Inc. and Strs Ohio. Company insiders that have sold Intersect ENT company stock in the last year include Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.
Which major investors are buying Intersect ENT stock?
XENT stock was bought by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, SG Americas Securities LLC, Amundi Pioneer Asset Management Inc., Pura Vida Investments LLC, Broadfin Capital LLC, Geode Capital Management LLC, Geode Capital Management LLC and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for Intersect ENT.
How do I buy shares of Intersect ENT?
Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intersect ENT's stock price today?
One share of XENT stock can currently be purchased for approximately $31.42.
How big of a company is Intersect ENT?
Intersect ENT has a market capitalization of $967.74 million and generates $108.47 million in revenue each year. The medical equipment provider earns $-22,920,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.
What is Intersect ENT's official website?
How can I contact Intersect ENT?
Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]
MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
